Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (Q34586436)

3 August 2017

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (English)

1 reference

metastatic renal cell carcinoma

3 August 2017

phase III clinical trial

0 references

1 reference

1 reference

1 reference

Agnieszka Jagiello-Gruszfeld

inferred from title

author

14

object named as

Agnieszka Jagiello-Gruszfeld

0 references

Bernard Escudier

1

object named as

Bernard Escudier

1 reference

3 August 2017

Alain Ravaud

4

0 references

Jacques-Olivier Bay

12

object named as

Jacques-Olivier Bay

1 reference

3 August 2017

6

Cezary Szczylik

1 reference

3 August 2017

2

Anna Pluzanska

1 reference

3 August 2017

Piotr Koralewski

3

1 reference

3 August 2017

Sergio Bracarda

5

1 reference

3 August 2017

Christine Chevreau

7

1 reference

3 August 2017

Marek Filipek

8

1 reference

3 August 2017

Bohuslav Melichar

9

1 reference

3 August 2017

Emilio Bajetta

10

1 reference

3 August 2017

Vera Gorbunova

11

1 reference

3 August 2017

Istvan Bodrogi

13

1 reference

3 August 2017

Nicola Moore

15

1 reference

3 August 2017

AVOREN Trial investigators

16

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

3 August 2017

1 reference

3 August 2017

370

1 reference

3 August 2017

9605

1 reference

3 August 2017

2103-2111

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Renal cancer: molecular mechanisms and newer therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

1 reference

7 January 2021

Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Bevacizumab for patients with metastatic renal cancer: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Interim analysis: the alpha spending function approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Treatment for renal cancer: are we beyond the cytokine era?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Impact of immune parameters on long-term survival in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961904-7

7 January 2021

Immunotherapy for advanced renal cell cancer.

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425

Identifiers

DOI

10.1016/S0140-6736(07)61904-7

1 reference

3 August 2017

1 reference